@Vobg $TYME Maybe the best update I currently have available. Taken from the December 2020 Eagle investors' presentation. I **think** 3rd line is the application area in which SM-88 has orphan drug designation. Aside from developmental/commercial benefits this means a "fast track" process for FDA evaluation. Good article here about results in clinical trials as of from previous trials; onclive.com/view/fda-grants...
1
1 Like